Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma
- 12 May 2010
- journal article
- research article
- Published by Informa UK Limited in Scandinavian Journal of Urology and Nephrology
- Vol. 44 (5), 284-290
- https://doi.org/10.3109/00365599.2010.485578
Abstract
The reactive stroma of prostate cancer contains a mixture of myofibroblasts and fibroblasts, while fully differentiated smooth-muscle cells are very rare or absent. In experimental prostate cancer models, prostatic stromal cells promote angiogenesis and stimulate prostate tumorigenesis. The aim of this study is to analyse whether the intensity of stromal changes can predict survival in patients with prostatic carcinoma. Stromal reaction was quantified histochemically and imunohistochemically in 50 patients treated with radical prostatectomy for clinically localized prostate carcinoma and its relationship with established prognostic factors was assessed. Kaplan-Meier analysis showed a significant association between the pattern of vimentin and desmin expression and the length of disease-free period; patients with a higher vimentin or lower desmin expression had a shorter disease-free period. On multivariate analysis only vimentin expression (odds ratio 4.06, 95% confidence interval 1.01-16.26, p = 0.049) was a significant predictor of biochemical recurrence. In patients with identical Gleason pattern and Gleason score the level of vimentin expression could identify patients with a higher risk of disease recurrence. Intensity of stromal changes could serve as an independent prognostic factor in the assessment of biochemical recurrence-free survival. Among prostate cancer patients with an identical Gleason score, it could identify patients with a higher risk of biochemical recurrence. Thus, stromal changes and their intensity could serve as a novel marker for the recognition of patients with an increased risk of disease recurrence.Keywords
This publication has 26 references indexed in Scilit:
- Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progressionSeminars in Cell & Developmental Biology, 2010
- Cancer-associated fibroblasts and tumor growth – bystanders turning into key playersCurrent Opinion in Genetics & Development, 2009
- Fibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?Journal of Cellular Biochemistry, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Role of tissue stroma in cancer cell invasionThe Journal of Pathology, 2003
- There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesionsJournal of Clinical Pathology, 2003
- Epithelial to Mesenchymal Transition in Human Breast Cancer Can Provide a Nonmalignant StromaThe American Journal of Pathology, 2003
- The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells.JCI Insight, 1995
- A fibroblast-associated antigen: characterization in fibroblasts and immunoreactivity in smooth muscle differentiated stromal cells.Journal of Histochemistry & Cytochemistry, 1992
- Alpha-smooth muscle actin, a differentiation marker of smooth muscle cells, is present in microfilamentous bundles of pericytes.Journal of Histochemistry & Cytochemistry, 1989